|
|
Blood, Vol. 111, Issue 4, 2170-2180, February 15, 2008
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Blood Boehrer et al.
111: 2170
Supplemental material for: Boehrer et al
Files in this Data Supplement:
- Figure S1. Effects of PDGFRα, PDGFRβ and Src on STAT-5 phosphorylation, apoptosis and differentiation in malignant myeloblasts (PDF, 323 KB). -
Effective knockdown of PDGFR , PDGFR or Src with specific siRNA were determined by immunoblot, 48 h after transfection (insert in F). (A, B) Effects of PDGFR, PDGFR and Src knockdown on the STAT-5 phosphorylation of KG-1 cells. The level of STAT-5 phosphorylation was determined by immunofluorescence staining with a phospho-neoepitopespecific antibody (compared to isotype controls in grey) as in Figure 5B and C. Representative FACS histograms in A are complemented with quantitations of triplicates (X±SD) in B. (C, D) Apoptosis-induction by PDGFR, PDGFR and Src knockdown, alone or in combination with erlotinib. Representative Annexin V/PI stainings are shown for KG-1 cells in C, while quantitative data are represented in D. Cells were transfected and incubated as described in Figure 5D. (E, F) Effects of PDGFR, PDGFR and Src depletion on erlotinib-induced differentiation of HL60 cells. Cells were cultured 3 days in the presence of erlotinib (added 24h after transfection) when expression of the monocytic differentiaton marker CD11b was determined by surface immunofluorescence labeling. Representative FACS histograms (compared to isotype controls in grey) are shown in E, and data are quantified in F.
|
|
